Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Trastuzumab in Metastatic Pancreatic Cancer
NCT00923299Phase 2Completed
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Dec 2008
- Primary completion
- Apr 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, KL-140 in pancreatic cancer (PC), sponsored by Institut du Cancer de Montpellier. Started Dec 2008; status: completed.
02
Drugs
trastuzumabKL-140
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00923299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923299.